Quest Laboratories Ltd. – Company Report
1. Company Overview
Quest Laboratories Ltd., incorporated in 1998 and headquartered in Dhar, Madhya Pradesh, is a diversified pharmaceutical manufacturing and marketing company focused on high-quality generic, branded, and OTC formulations. The company holds WHO Schedule M GMP, GLP, ISO 9001:2015, and ISO/IEC 17025:2017 certifications, underscoring its commitment to stringent quality and global regulatory compliance.
Quest supplies pharmaceutical products across institutional, private, and government channels—including contract manufacturing, PCD, ethical marketing, exports, and government tenders. Backed by in-house R&D, Quality Control, and Quality Assurance, it covers a broad therapeutic spectrum and a wide range of dosage forms. The company is actively expanding its presence across India and select overseas markets.
Key Highlights
- Incorporated: 1998
- Headquarters: Dhar, Madhya Pradesh, India
- Employees: 83 (manufacturing, QC, technical, admin, logistics)
- Certifications: WHO-GMP, GLP, GMP (Schedule M), ISO 9001:2015, ISO/IEC 17025:2017
- Manufacturing: 900+ FDA-approved formulations; 250–300 actively manufactured
- Distribution: Presence in 12 states and 2 union territories
- Market Focus: Government tenders, private institutions, exports, contract manufacturing
- R&D: In-house team for formulation development, analytics, and compliance
- Promoters: Mr. Anil Kumar Sabarwal (Chairman & Managing Director)
2. Products and Services
Quest Laboratories offers a wide-ranging product portfolio catering to various therapeutic needs:
Therapeutic Classes: Antibiotics, antimalarials, anti-inflammatories, antidiabetics, antispasmodics, antidepressants, antiemetics, respiratory care, pain relief, gastroenterology, vitamins, and nutraceuticals.
Dosage Forms:
- Tablets: uncoated, film/enteric coated, sustained-release
- Capsules: hard and soft gelatin
- Oral liquids: syrups, elixirs, suspensions
- Oral powders: dry syrups, oral rehydration salts (ORS)
- Injectables: vials, ampoules (including anticancer drugs)
- Topicals: ointments, creams
- External liquids: antiseptics, sanitizers
Specialty & Technology-Driven Offerings:
- Fast-dissolving, sustained-release, and bitter-masked formulations
- Anti-retroviral and complex generics
Service Offerings:
- Contract Manufacturing for domestic and international pharma brands
- Institutional Supply through central/state government tenders
- PCD/Franchise Marketing and private-label partnerships
Quest emphasizes affordable healthcare with robust formulation quality, leveraging its R&D to offer competitive, innovation-driven pharmaceutical solutions.
3. Recent News and Business Developments
- R&D Expansion: Enhanced in-house capabilities in complex generics and specialty formulations
- New Injectable Sections Added: Set up for vials, ampoules, and anticancer drugs
- Government Incentives: Benefited from MSME promotion schemes, aiding capex and lowering interest costs
- Export Growth Strategy: Strengthening presence in select regulated and semi-regulated markets
- Promoter Stake Increase (Jan 2025): On January 2, 2025, CMD Mr. Anil Kumar Sabarwal acquired 33,600 equity shares (0.205% of equity), increasing his stake beyond 62.04%. This reaffirms promoter confidence and long-term strategic commitment to the company.
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹108.16 crore (↑ 30.6% YoY) |
| Net Profit (PAT) | ₹13.57 crore (↑ 34.4% YoY) |
| Operating Profit Margin | 18.85% (vs. 18.42% in FY2024) |
| Net Profit Margin | 13.05% (vs. 12.22% in FY2024) |
| EPS | ₹8.28 |
| Debt | Very low; minimal interest burden |
| Dividend | Not declared; focus on reinvestment |